clinical trial · NCT03891446
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie·phase3·active not recruiting·n = 455
Open-Angle GlaucomaOcular HypertensionBimatoprost SRStandard of Care
brief summary
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
started
Mar 27, 2019
primary completion
Jul 1, 2026
completion
Aug 1, 2026
last updated
Aug 28, 2025
official title
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol